Randomized trial evaluated a dual-modular CAR-T platform targeting FAP, revealing promising outcomes in solid tumors and a patient.
Key Points
The study aims to develop and evaluate a dual-modular nanobody CAR-T cell platform for solid tumors, particularly addressing challenges in antigen heterogeneity and immunosuppression.
CAR-T cells were engineered to target fibroblast activation protein and deliver an anti-CTLA-4 nanobody locally.
Efficacy was assessed through in vitro assays and in vivo xenograft models measuring tumor growth, survival, and T-cell infiltration.
Clinical administration in a patient with glioblastoma included monitoring of CSF cytokines and safety.
In vitro CAR-T cells demonstrated potent cytotoxicity and cytokine production with reduced exhaustion.
In vivo studies showed significant tumor regression and prolonged survival with increased T-cell infiltration.
The glioblastoma patient experienced disease stabilization and favorable safety profile after intrathecal administration.